Free Trial

Accuray logo with Medical background

Key Points

  • Accuray has been downgraded by Wall Street Zen from a "hold" rating to a "sell" rating, reflecting a negative outlook from some analysts.
  • Despite the downgrade, BTIG Research has raised its price target for Accuray from $4.00 to $5.00, maintaining a "buy" rating for the stock.
  • Accuray reported $0.01 earnings per share in its latest quarter, missing expectations, while revenue slightly exceeded forecasts at $127.54 million.
  • Five stocks to consider instead of Accuray.
Like this article? Share it with a colleague.